rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2022-131-148rsp-3145Research ArticleПЕРЕДОВАЯLEADING ARTICLEИнгибиторы Янус-киназ при иммуновоспалительных заболеваниях: 10 лет клинической практики в ревматологииJanus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatologyhttps://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

Насонов Евгений Львович

115522, Москва, Каширское шоссе, 34а; 119991, Москва, ул. Трубецкая, 8, стр. 2

Еvgeny L. Nasonov

119991, Moscow, Trubetskaya str., 8, building 2; 115522, Moscow, Kashirskoye Highway, 34A

nasonov@irramn.ruhttps://orcid.org/0000-0003-0579-1131КоротаеваТ. В.KorotaevaT. V.

115522, Москва, Каширское шоссе, 34а

Tatiana V. Korotaeva

115522, Moscow, Kashirskoye Highway, 34A

ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой; ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Russian FederationФГБНУ Научноисследовательский институт ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202213052022602131148Copyright © Насонов Е.Л., Коротаева Т.В., 20222022Насонов Е.Л., Коротаева Т.В.Nasonov E.L., Korotaeva T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3145

Несмотря на большие успехи в диагностике и лечении иммуновоспалительных ревматических заболеваний (ИВРЗ), приведшие к существенному улучшению прогноза у многих пациентов, центральные медицинские проблемы этой патологии – восстановление качества жизни и снижение летальности до популяционного уровня – далеки от разрешения. Это послужило мощным стимулом к изучению новых подходов к фармакотерапии ИВРЗ, один из которых связан с использованием низкомолекулярных химически синтезированных препаратов, ингибирующих внутриклеточные «сигнальные» молекулы – Янус-киназ (JAK, Janus kinase). Рассмотрены современные достижения, тенденции и рекомендации, касающиеся применения ингибиторов JAK в лечении ИВРЗ и COVID-19.

Despite great advances in the diagnosis and treatment of Immune-mediated inflammatory diseases (IMIDs), which have led to a significant improvement in the prognosis in many patients, the central medical problems of this pathology – restoring the quality of life and reducing mortality to the population level – are far from being resolved. This served as a powerful stimulus for the study of new approaches to the pharmacotherapy of IMIDs, one of which is associated with the discovery of targets for small-molecule therapeutics that inhibit intracellular “signaling” molecules JAKs (Janus kinases). The current achievements, trends and recommendations regarding the use of JAK inhibitors in the treatment of IMIDs and also in the hyper-response phase of COVID-19 are reviewed.

иммуновоспалительные ревматические заболеванияревматоидный артритспондилоартритыпсориатический артритцитокиныингибиторы JAKтофацитиниббарицитинибупадацитинибCOVID-19immune-mediated inflammatory diseasesrheumatoid arthritisspondyloarthritispsoriatic arthritiscytokinesJAK inhibitorstofacitinibbaricitinibupadacitinibCOVID-19ReferencesMcGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):e297. doi: 10.1371/journal.pmed.0030297McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):e297. doi: 10.1371/journal.pmed.0030297Szekanecz Z, McInnes IB, Schett G, Szamosi S, Benkő S, Szűcs G. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17(10):585-595. doi: 10.1038/s41584-021-00652-9Szekanecz Z, McInnes IB, Schett G, Szamosi S, Benkő S, Szűcs G. Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol. 2021;17(10):585-595. doi: 10.1038/s41584-021-00652-9Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med. 2021;385(7):628-639. doi: 10.1056/NEJMra1909094Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med. 2021;385(7):628-639. doi: 10.1056/NEJMra1909094van Wesemael T, Huizinga TW, Toes REM, van der Woude D. From phenotype to pathophysiology – placing rheumatic diseases in an immunological perspective. Lancet Rheumatol. 2022;4(3):E166-E167. doi: 10.1016/S2665-9913(21)00369-6van Wesemael T, Huizinga TW, Toes REM, van der Woude D. From phenotype to pathophysiology – placing rheumatic diseases in an immunological perspective. Lancet Rheumatol. 2022;4(3):E166-E167. doi: 10.1016/S2665-9913(21)00369-6Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-187. doi: 10.1136/annrheumdis-2017-211555Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-187. doi: 10.1136/annrheumdis-2017-211555Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-419. doi: 10.14412/1995-44842017-409-419Nasonov EL. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):409-419 (In Russ.). doi: 10.14412/1995-44842017-409-419Burmester GR, Bijlsma JWJ, Cutolo M, McInnes IB. Managing rheumatic and musculoskeletal diseases – past, present and future. Nat Rev Rheumatol. 2017;13(7):443-448. doi: 10.1038/nrrheum.2017.95Burmester GR, Bijlsma JWJ, Cutolo M, McInnes IB. Managing rheumatic and musculoskeletal diseases – past, present and future. Nat Rev Rheumatol. 2017;13(7):443-448. doi: 10.1038/nrrheum.2017.95S chwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843862. doi: 10.1038/nrd.2017.201S chwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843862. doi: 10.1038/nrd.2017.201Насонов ЕЛ, Лила АМ. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16. doi: 10.14412/1995-4484-2019-8-16Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: New opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):8-16 (In Russ.). doi: 10.14412/1995-4484-2019-8-16Spinelli FR, Meylan F, O’Shea JJ, Gadina M. JAK inhibitors: Ten years after. Eur J Immunol. 2021;51(7):1615-1627. doi: 10.1002/eji.202048922Spinelli FR, Meylan F, O’Shea JJ, Gadina M. JAK inhibitors: Ten years after. Eur J Immunol. 2021;51(7):1615-1627. doi: 10.1002/eji.202048922O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161170. doi: 10.1056/NEJMra1202117O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161170. doi: 10.1056/NEJMra1202117Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133-145. doi: 10.1038/s41584-02100726-8Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133-145. doi: 10.1038/s41584-02100726-8McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet. 2021;398(10302):803-816. doi: 10.1016/S0140-6736(21)00438-4McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet. 2021;398(10302):803-816. doi: 10.1016/S0140-6736(21)00438-4Liu C, Kieltyka J, Fleischmann R, Gadina M, O’Shea JJ. A decade of JAK inhibitors: What have we learned and what may be the future? Arthritis Rheumatol. 2021;73(12):2166-2178. doi: 10.1002/art.41906Liu C, Kieltyka J, Fleischmann R, Gadina M, O’Shea JJ. A decade of JAK inhibitors: What have we learned and what may be the future? Arthritis Rheumatol. 2021;73(12):2166-2178. doi: 10.1002/art.41906McInnes IB, Byers NL, Higgs RE, Lee J, Macias WL, Na S, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183. doi: 10.1186/s13075-0191964-1McInnes IB, Byers NL, Higgs RE, Lee J, Macias WL, Na S, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183. doi: 10.1186/s13075-0191964-1Choy EH. Clinical significance of Janus kinase inhibitor selectivity. Rheumatology (Oxford). 2019;58(6):953-962. doi: 10.1093/rheumatology/key339Choy EH. Clinical significance of Janus kinase inhibitor selectivity. Rheumatology (Oxford). 2019;58(6):953-962. doi: 10.1093/rheumatology/key339Dowty ME, Lin TH, Jesson MI, Hegen M, Martin DA, Katkade V, et al. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect. 2019;7(6):e00537. doi: 10.1002/prp2.537Dowty ME, Lin TH, Jesson MI, Hegen M, Martin DA, Katkade V, et al. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect. 2019;7(6):e00537. doi: 10.1002/prp2.537Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80(7):865-875. doi: 10.1136/annrheumdis-2020-219012Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80(7):865-875. doi: 10.1136/annrheumdis-2020-219012Kubo S, Nakayamada S, Sakata K, Kitanaga Y, Ma X, Lee S, et al. Janus kinase inhibitor baricitinib modulates human innate and adaptive immune system. Front Immunol. 2018;9:1510. doi: 10.3389/fimmu.2018.01510Kubo S, Nakayamada S, Sakata K, Kitanaga Y, Ma X, Lee S, et al. Janus kinase inhibitor baricitinib modulates human innate and adaptive immune system. Front Immunol. 2018;9:1510. doi: 10.3389/fimmu.2018.01510Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis. 2014;73(12):2192-2198. doi: 10.1136/annrheumdis-2013-203756Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis. 2014;73(12):2192-2198. doi: 10.1136/annrheumdis-2013-203756Moura RA, Fonseca JE. JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis. Front Med (Lausanne). 2021;7:607725. doi: 10.3389/fmed.2020.607725Moura RA, Fonseca JE. JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis. Front Med (Lausanne). 2021;7:607725. doi: 10.3389/fmed.2020.607725Sornasse T, Sokolove J, McInnes I. Treatment with upadacitinib: Results in the normalization of key pathobiologic pathways in patients with rheumatoid arthritis [Abstract]. Arthritis Rheumatol. 2019;71(Suppl 10). URL: https://acrabstracts.org/abstract/treatment-with-upadacitinib-results-in-the-normalization-of-key-pathobiologic-pathways-in-patients-with-rheumatoidarthritis/ (Accessed: 21st August 2020).Sornasse T, Sokolove J, McInnes I. Treatment with upadacitinib: Results in the normalization of key pathobiologic pathways in patients with rheumatoid arthritis [Abstract]. Arthritis Rheumatol. 2019;71(Suppl 10). URL: https://acrabstracts.org/abstract/treatment-with-upadacitinib-results-in-the-normalization-of-key-pathobiologic-pathways-in-patients-with-rheumatoidarthritis/ (Accessed: 21st August 2020).Lent S, Sornasse T, Georgantas R, Sokolove J, McInnes I. Molecular analysis of the mode of action of upadacitinib in rheumatoid arthritis patients: Whole blood RNA expression data from the SELECT-NEXT study [Abstract]. Arthritis Rheumatol. 2019;71(Suppl 10). URL: https://acrabstracts.org/abstract/molecular-analysis-of-the-mode-of-action-of-upadacitinib-in-rheumatoid-arthritis-patients-whole-blood-rna-expression-data-from-theselect-next-study (Accessed: 21st August 2020).Lent S, Sornasse T, Georgantas R, Sokolove J, McInnes I. Molecular analysis of the mode of action of upadacitinib in rheumatoid arthritis patients: Whole blood RNA expression data from the SELECT-NEXT study [Abstract]. Arthritis Rheumatol. 2019;71(Suppl 10). URL: https://acrabstracts.org/abstract/molecular-analysis-of-the-mode-of-action-of-upadacitinib-in-rheumatoid-arthritis-patients-whole-blood-rna-expression-data-from-theselect-next-study (Accessed: 21st August 2020).Sornasse T, Song IH, Radstake T, McInnes I. FRI0026. Proteomics analysis comparing the mode of action of upadacitinib and adalimumab head to head in RA identifies novel, discrete early immune pathway modulation in the SELECT-COMPARE phase 3 study. Ann Rheum Dis. 2020;79:585-586. doi: 10.1136/annrheumdis-2020-eular.1908Sornasse T, Song IH, Radstake T, McInnes I. FRI0026. Proteomics analysis comparing the mode of action of upadacitinib and adalimumab head to head in RA identifies novel, discrete early immune pathway modulation in the SELECT-COMPARE phase 3 study. Ann Rheum Dis. 2020;79:585-586. doi: 10.1136/annrheumdis-2020-eular.1908Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in inflammatory and autoimmune diseases. BioDrugs. 2019;33(1):15-32. doi: 10.1007/s40259-019-00333Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in inflammatory and autoimmune diseases. BioDrugs. 2019;33(1):15-32. doi: 10.1007/s40259-019-00333Fragoulis GE, Brock J, Basu N, McInnes IB, Siebert S. The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. J Allergy Clin Immunol. 2021;148(4):941952. doi: 10.1016/j.jaci.2021.08.010Fragoulis GE, Brock J, Basu N, McInnes IB, Siebert S. The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. J Allergy Clin Immunol. 2021;148(4):941952. doi: 10.1016/j.jaci.2021.08.010Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014;73(1):3-5. doi: 10.1136/annrheumdis-2013-204317Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014;73(1):3-5. doi: 10.1136/annrheumdis-2013-204317Насонов ЕЛ, Авдеева АС, Лила АМ. Эффективность и безопасность тофацитиниба при иммуновоспалительных ревматических заболеваниях (часть I). Научно-практическая ревматология. 2020;58(1):62-79. doi: 10.14412/1995-4484-2020-62-79Nasonov EL, Avdeeva AS, Lila AM. Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2020;58(1):62-79 (In Russ.). doi: 10.14412/1995-4484-2020-62-79Насонов ЕЛ, Авдеева АС, Лила АМ. Эффективность и безопасность тофацитиниба при иммуновоспалительных ревматических заболеваниях (часть II). Научно-практическая ревматология. 2020;58(2):214-224. doi: 10.14412/1995-4484-2020214-224Nasonov EL, Avdeeva AS, Lila AM. Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (part II). NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2020;58(2):214-224 (In Russ.). doi: 10.14412/1995-4484-2020214-224Насонов ЕЛ, Лила АМ. Барицитиниб: новые возможности фармакотерапии ревматоидного артрита и других иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2020;58(3):304-316. doi: 10.14412/1995-4484-2020-304-316Nasonov EL, Lila AM. Baricitinib: New pharmacotherapy options for rheumatoid arthritis and other immune-mediated inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2020;58(3):304-316 (In Russ.). doi: 10.14412/1995-4484-2020-304-316Насонов ЕЛ, Лила АМ. Перспективы применения упадацитиниба при ревматоидном артрите и других иммуно-воспалительных ревматических заболеваниях. Научно-практическая ревматология. 2020;58(5):532-543. doi: 10.47360/1995-4484-2020-532-543Nasonov EL, Lila AM. The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2020;58(5):532-543 (In Russ.). doi: 10.47360/1995-4484-2020-532-543Насонов ЕЛ (ред.). Ревматология. Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2017. [Nasonov EL (ed.). Rheumatology. Russian clinical guidelines. Moscow:GEOTARMedia;2020 (In Russ.)].Насонов ЕЛ (ред.). Ревматология. Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2017. [Nasonov EL (ed.). Rheumatology. Russian clinical guidelines. Moscow:GEOTARMedia;2020 (In Russ.)].Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108-1123. doi: 10.1002/art.41752Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108-1123. doi: 10.1002/art.41752Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700-712. doi: 10.1136/annrheumdis-2020-217159Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700-712. doi: 10.1136/annrheumdis-2020-217159Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al.; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the manage ment of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al.; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the manage ment of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484Amiot A, Bouguen G, Bonnaud G, Bouhnik Y, Hagege H, PeyrinBiroulet L; French National Consensus Clinical guidelines for the management of IBD study group. Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus. Dig Liver Dis. 2021;53(1):35-43. doi: 10.1016/j.dld.2020.10.018Amiot A, Bouguen G, Bonnaud G, Bouhnik Y, Hagege H, PeyrinBiroulet L; French National Consensus Clinical guidelines for the management of IBD study group. Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus. Dig Liver Dis. 2021;53(1):35-43. doi: 10.1016/j.dld.2020.10.018Nwaogu A, Bond A, Smith PJ. Guideline review: Tofacitinib for adults with moderately to severely active ulcerative colitis – NICE guidance. Frontline Gastroenterol. 2020;12(2):133-136. doi: 10.1136/flgastro-2020-101502Nwaogu A, Bond A, Smith PJ. Guideline review: Tofacitinib for adults with moderately to severely active ulcerative colitis – NICE guidance. Frontline Gastroenterol. 2020;12(2):133-136. doi: 10.1136/flgastro-2020-101502Kerschbaumer A, Smolen JS, Nash P, Doerner T, Dougados M, Fleischmann R, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: A systematic literature research. RMD Open. 2020;6(3):e001374. doi: 10.1136/rmdopen-2020-001374Kerschbaumer A, Smolen JS, Nash P, Doerner T, Dougados M, Fleischmann R, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: A systematic literature research. RMD Open. 2020;6(3):e001374. doi: 10.1136/rmdopen-2020-001374Reddy V, Cohen S. Role of Janus kinase inhibitors in rheumatoid arthritis treatment. Curr Opin Rheumatol. 2021;33(3):300-306. doi: 10.1097/BOR.0000000000000792Reddy V, Cohen S. Role of Janus kinase inhibitors in rheumatoid arthritis treatment. Curr Opin Rheumatol. 2021;33(3):300-306. doi: 10.1097/BOR.0000000000000792Tóth L, Juhász MF, Szabó L, Abada A, Kiss F, Hegyi P, et al. Janus kinase inhibitors improve disease activity and patient-reported outcomes in rheumatoid arthritis: A systematic review and metaanalysis of 24,135 patients. Int J Mol Sci. 2022;23(3):1246. doi: 10.3390/ijms23031246Tóth L, Juhász MF, Szabó L, Abada A, Kiss F, Hegyi P, et al. Janus kinase inhibitors improve disease activity and patient-reported outcomes in rheumatoid arthritis: A systematic review and metaanalysis of 24,135 patients. Int J Mol Sci. 2022;23(3):1246. doi: 10.3390/ijms23031246Strand V. RMD commentary, JAK kinase inhibitors: A preferred alternative to TNF inhibitors? RMD Open. 2021;7(1):e001565. doi: 10.1136/rmdopen-2021-001565Strand V. RMD commentary, JAK kinase inhibitors: A preferred alternative to TNF inhibitors? RMD Open. 2021;7(1):e001565. doi: 10.1136/rmdopen-2021-001565Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al.; T2T Expert Committee. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631-637. doi: 10.1136/ard.2009.123919Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al.; T2T Expert Committee. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631-637. doi: 10.1136/ard.2009.123919Maassen JM, van Ouwerkerk L, Allaat CF. Tapering of diseasesmodifying antirheumatic drugs: an overview for daily practice. Lancet Rheumatol. 2021;3:e659-e670.Maassen JM, van Ouwerkerk L, Allaat CF. Tapering of diseasesmodifying antirheumatic drugs: an overview for daily practice. Lancet Rheumatol. 2021;3:e659-e670.Kubo S, Yamaoka K, Amano K, Nagano S, Tohma S, Suematsu E, et al. Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: A multicentre, observational study. Rheumatology (Oxford). 2017;56(8):1293-1301. doi: 10.1093/rheumatology/kex068Kubo S, Yamaoka K, Amano K, Nagano S, Tohma S, Suematsu E, et al. Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: A multicentre, observational study. Rheumatology (Oxford). 2017;56(8):1293-1301. doi: 10.1093/rheumatology/kex068Pérez-Román DI, Ortiz-Haro AB, Ruiz-Medrano E, ContrerasYáñez I, Pascual-Ramos V. Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation. Rheumatol Int. 2018;38(4):599-606. doi: 10.1007/s00296-017-3910-3Pérez-Román DI, Ortiz-Haro AB, Ruiz-Medrano E, ContrerasYáñez I, Pascual-Ramos V. Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation. Rheumatol Int. 2018;38(4):599-606. doi: 10.1007/s00296-017-3910-3Mori S, Ueki Y Outcomes of dose reduction, withdrawal, and restart of tofacitinib in patients with rheumatoid arthritis: A prospective observational study. Clin Rheumatol. 2019;38(12):3391-3400. doi: 10.1007/s10067-019-04721-zMori S, Ueki Y Outcomes of dose reduction, withdrawal, and restart of tofacitinib in patients with rheumatoid arthritis: A prospective observational study. Clin Rheumatol. 2019;38(12):3391-3400. doi: 10.1007/s10067-019-04721-zKaine J, Tesser J, DeMasi R, Takiya L, Wang L, Slyder M, et al. Efficacy of tofacitinib after temporary discontinuation in patients with rheumatoid arthritis: Analysis of data from open-label longterm extension studies. Ann Rheum Dis. 2018. doi: 10/1136/annrheumdis-2018-eular.3755Kaine J, Tesser J, DeMasi R, Takiya L, Wang L, Slyder M, et al. Efficacy of tofacitinib after temporary discontinuation in patients with rheumatoid arthritis: Analysis of data from open-label longterm extension studies. Ann Rheum Dis. 2018. doi: 10/1136/annrheumdis-2018-eular.3755Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Klar R, et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: Results of a prospective study. Ann Rheum Dis. 2019;78(2):171-178. doi: 10.1136/annrheumdis-2018-213271Takeuchi T, Genovese MC, Haraoui B, Li Z, Xie L, Klar R, et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: Results of a prospective study. Ann Rheum Dis. 2019;78(2):171-178. doi: 10.1136/annrheumdis-2018-213271Cohen SB, Pope J, Haraoui B, Irazoque-Palazuelos F, Korkosz M, Diehl A, et al. Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): A randomised, phase 3b/4, non-inferiority trial. Lancet Rheumatol. 2019;1:e23-e34. doi: 10.1016/S26659913(19)30005-0Cohen SB, Pope J, Haraoui B, Irazoque-Palazuelos F, Korkosz M, Diehl A, et al. Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): A randomised, phase 3b/4, non-inferiority trial. Lancet Rheumatol. 2019;1:e23-e34. doi: 10.1016/S26659913(19)30005-0Cohen SB, Pope J, Haraoui B, Mysler E, Diehl A, Lukic T, et al. Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift). RMD Open. 2021;7(2):e001673. doi: 10.1136/rmdopen-2021-001673Cohen SB, Pope J, Haraoui B, Mysler E, Diehl A, Lukic T, et al. Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift). RMD Open. 2021;7(2):e001673. doi: 10.1136/rmdopen-2021-001673Авдеева АС, Мисиюк АС, Сатыбалдыев АМ, Лукина ГВ, Сороцкая ВН, Жиляев ЕВ, и др. Анализ результатов терапии тофацитинибом в реальной клинической практике (по данным Общероссийского регистра больных артритом ОРЕЛ). Научнопрактическая ревматология. 2020;58(3):262-267. doi: 10.14412/1995-4484-2020-262-267Avdeeva AS, Misiyuk AS, Satybaldyev AM, Lukina GV, Sorotskaya VN, Zhilyaev EV, et al. Analysis of the results of tofacitinib therapy in real clinical practice according to the All-Russian Arthritis Registry (OREL). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2020;58(3):262-267 (In Russ.). doi: 10.14412/1995-4484-2020-262-267Campanaro F, Batticciotto A, Zaffaroni A, Cappelli A, Donadini MP, Squizzato A. JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis. Autoimmun Rev. 2021;20(10):102902. doi: 10.1016/j.autrev.2021.102902Campanaro F, Batticciotto A, Zaffaroni A, Cappelli A, Donadini MP, Squizzato A. JAK inhibitors and psoriatic arthritis: A systematic review and meta-analysis. Autoimmun Rev. 2021;20(10):102902. doi: 10.1016/j.autrev.2021.102902Keeling S, Maksymowych WP. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: A critical review of clinical trials. Expert Rev Clin Immunol. 2021;17(7):701-715. doi: 10.1080/1744666X.2021.1925541Keeling S, Maksymowych WP. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: A critical review of clinical trials. Expert Rev Clin Immunol. 2021;17(7):701-715. doi: 10.1080/1744666X.2021.1925541Akkoc N, Khan MA. JAK inhibitors for axial spondyloarthritis: What does the future hold? Curr Rheumatol Rep. 2021;23(6):34. doi: 10.1007/s11926-021-01001-1Akkoc N, Khan MA. JAK inhibitors for axial spondyloarthritis: What does the future hold? Curr Rheumatol Rep. 2021;23(6):34. doi: 10.1007/s11926-021-01001-1Lee YH, Song GG. Janus kinase inhibitors for treating active ankylosing spondylitis: A meta-analysis of randomized controlled trials. Z Rheumatol. 2022;81(1):71-76. doi: 10.1007/s00393-02000948-3Lee YH, Song GG. Janus kinase inhibitors for treating active ankylosing spondylitis: A meta-analysis of randomized controlled trials. Z Rheumatol. 2022;81(1):71-76. doi: 10.1007/s00393-02000948-3van der Heijde D, Deodhar A, Wei JC, Drescher E, Fleishaker D, Hendrikx T, et al.. Tofacitinib in patients with ankylosing spondylitis: A phase II, 16-week, randomised, placebo-controlled, doseranging study. Ann Rheum Dis. 2017;76(8):1340-1347. doi: 10.1136/annrheumdis-2016-210322van der Heijde D, Deodhar A, Wei JC, Drescher E, Fleishaker D, Hendrikx T, et al.. Tofacitinib in patients with ankylosing spondylitis: A phase II, 16-week, randomised, placebo-controlled, doseranging study. Ann Rheum Dis. 2017;76(8):1340-1347. doi: 10.1136/annrheumdis-2016-210322Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, et al. Tofacitinib for the treatment of ankylosing spondylitis: A phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80(8):1004-1013. doi: 10.1136/annrheumdis-2020-219601Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, et al. Tofacitinib for the treatment of ankylosing spondylitis: A phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80(8):1004-1013. doi: 10.1136/annrheumdis-2020-219601van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): A multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019;394(10214):21082117. doi: 10.1016/S0140-6736(19)32534-6van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): A multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019;394(10214):21082117. doi: 10.1016/S0140-6736(19)32534-6Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537-1550. doi: 10.1056/NEJMoa1615975Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537-1550. doi: 10.1056/NEJMoa1615975Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525-1536. doi: 10.1056/NEJMoa1615977Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525-1536. doi: 10.1056/NEJMoa1615977McInnes IB, Kato K, Magrey M, Merola JF, Kishimoto M, Pacheco-Tena C, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open. 2021;7(3):e001838. doi: 10.1136/rmdopen-2021-001838McInnes IB, Kato K, Magrey M, Merola JF, Kishimoto M, Pacheco-Tena C, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open. 2021;7(3):e001838. doi: 10.1136/rmdopen-2021-001838Mease PJ, Lertratanakul A, Anderson JK, Papp K, van den Bosch F, Tsuji S, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2020;80(3):312-320. doi: 10.1136/annrheumdis-2020-218870Mease PJ, Lertratanakul A, Anderson JK, Papp K, van den Bosch F, Tsuji S, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2020;80(3):312-320. doi: 10.1136/annrheumdis-2020-218870Логинова ЕЮ, Корсакова ЮЛ, Губарь ЕЕ, Карпова ПЛ, Коротаева ТВ. Эффективность и безопасность тофацитиниба у больных псориатическим артритом в реальной клинической практике. Научно-практическая ревматология. 2020;58(3):268275. doi: 10.14412/1995-4484-2020268-275Loginova EYu, Korsakova YuL, Gubar EE, Karpova PL, Korotaeva TV. Efficacy and safety of tofacitinib in patients with psoriatic arthritis in real clinical practice. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2020;58(3):268-275 (In Russ.). doi: 10.14412/1995-4484-2020268-275Губарь ЕЕ, Корсакова ЮЛ, Логинова ЕЮ, Смирнов АВ, Глухова СИ, Коротаева ТВ. Влияние терапии тофацитинибом на динамику активного сакроилиита у больных псориатическим артритом. Научно-практическая ревматология. 2021;59(2):134-140. doi: 10.47360/19954484-2021-134-140Gubar EE, Korsakova YuL, Loginova EYu, Smirnov AV, Glukhova SI, Korotaeva TV. Effect of tofacitinib treatment on active MRI sacroiliitis in psoriatic arthritis patients. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2021;59(2):134-140 (In Russ.). doi: 10.47360/19954484-2021-134-140Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1(1):e000019. doi: 10.1136/rmdopen-2014-000019Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1(1):e000019. doi: 10.1136/rmdopen-2014-000019Rendas-Baum R, Bayliss M, Kosinski M, Raju A, Zwillich SH, Wallenstein GV, et al. Measuring the effect of therapy in rheumatoid arthritis clinical trials from the patient’s perspective. Curr Med Res Opin. 2014;30:1391-1403. doi: 10.1185/03007995.2014.896328Rendas-Baum R, Bayliss M, Kosinski M, Raju A, Zwillich SH, Wallenstein GV, et al. Measuring the effect of therapy in rheumatoid arthritis clinical trials from the patient’s perspective. Curr Med Res Opin. 2014;30:1391-1403. doi: 10.1185/03007995.2014.896328Taylor P, Manger B, Alvaro-Gracia J, Johnstone R, GomezReino J, Eberhardt E, et al. Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. J Int Med Res. 2010;38:1213-1224. doi: 10.1177/147323001003800402Taylor P, Manger B, Alvaro-Gracia J, Johnstone R, GomezReino J, Eberhardt E, et al. Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. J Int Med Res. 2010;38:1213-1224. doi: 10.1177/147323001003800402Boyden SD, Hossain IN, Wohlfahrt A, Lee YC. Noninflammatory causes of pain in patients with rheumatoid arthritis. Curr Rheumatol Rep. 2016;18:30. doi: 10.1007/s11926-016-0581-0Boyden SD, Hossain IN, Wohlfahrt A, Lee YC. Noninflammatory causes of pain in patients with rheumatoid arthritis. Curr Rheumatol Rep. 2016;18:30. doi: 10.1007/s11926-016-0581-0Lampa JB. Pain without inflammation in rheumatic diseases. Best Pract Res Clin Rheumatol. 2019;33(3):101439. doi: 10.1016/j.berh.2019.101439Lampa JB. Pain without inflammation in rheumatic diseases. Best Pract Res Clin Rheumatol. 2019;33(3):101439. doi: 10.1016/j.berh.2019.101439Pazmino S, Lovik A, Boonen A, de Cock D, Stouten V, Bertrand D, et al. The discordance between patient-reported and clinical. Biological outcomes could help in FUTURE future disease impact in patients with rheumatoid arthritis. Ann Rheum Dis. 2021;80:484. doi: 10.1136/annrheumdis-2021-eular.4099Pazmino S, Lovik A, Boonen A, de Cock D, Stouten V, Bertrand D, et al. The discordance between patient-reported and clinical. Biological outcomes could help in FUTURE future disease impact in patients with rheumatoid arthritis. Ann Rheum Dis. 2021;80:484. doi: 10.1136/annrheumdis-2021-eular.4099Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: A current perspective. Rheumatol Int. 2016;36:685-695. doi: 10.1007/s00296-015-3415-xTaylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: A current perspective. Rheumatol Int. 2016;36:685-695. doi: 10.1007/s00296-015-3415-xКаратеев АЕ. Проблемы боли и качества жизни при ревматоидном артрите: фокус на барицитиниб. Научно-практическая ревматология. 2020;58(4):420-427. doi: 10.47360/1995-4484-2020-420-427Karateev AE. Problems of pain and quality of life in rheumatoid arthritis: Focus on baricitinib. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2020;58(4):420-427. (In Russ.). doi: 10.47360/1995-4484-2020-420-427Taylor PC, Lee YC, Fleischmann R, Takeuchi T, Perkins EL, Fautrel B, et al. Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: Results from the RA-BEAM trial. J Clin Med. 2019;8(6):831. doi: 10.3390/jcm8060831Taylor PC, Lee YC, Fleischmann R, Takeuchi T, Perkins EL, Fautrel B, et al. Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: Results from the RA-BEAM trial. J Clin Med. 2019;8(6):831. doi: 10.3390/jcm8060831Fautrel B, Kirkham B, Pope JE, Takeuchi T, Gaich C, Quebe A, et al. Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: Exploratory analyses from RA-BEAM. J Clin Med. 2019;8(9):1394. doi: 10.3390/jcm8091394Fautrel B, Kirkham B, Pope JE, Takeuchi T, Gaich C, Quebe A, et al. Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: Exploratory analyses from RA-BEAM. J Clin Med. 2019;8(9):1394. doi: 10.3390/jcm8091394Ogdie A, de Vlam K, McInnes IB, Mease PJ, Baer P, Lukic T, et al. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. RMD Open. 2020;6(1):e001042. doi: 10.1136/rmdopen-2019001042Ogdie A, de Vlam K, McInnes IB, Mease PJ, Baer P, Lukic T, et al. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. RMD Open. 2020;6(1):e001042. doi: 10.1136/rmdopen-2019001042Salaffi F, Giacobazzi G, Di Carlo M. Chronic pain in inflammatory arthritis: mechanisms, metrology, and emerging targets – A focus on the JAK-STAT Pathway. Pain Res Manag. 2018;2018:8564215. doi: 10.1155/2018/8564215Salaffi F, Giacobazzi G, Di Carlo M. Chronic pain in inflammatory arthritis: mechanisms, metrology, and emerging targets – A focus on the JAK-STAT Pathway. Pain Res Manag. 2018;2018:8564215. doi: 10.1155/2018/8564215Simon LS, Taylor PC, Choy EH, Sebba A, Quebe A, Knopp KL, et al. The Jak/STAT pathway: A focus on pain in rheumatoid arthritis. Semin Arthritis Rheum. 2021;51(1):278-284. doi: 10.1016/j.semarthrit.2020.10.008Simon LS, Taylor PC, Choy EH, Sebba A, Quebe A, Knopp KL, et al. The Jak/STAT pathway: A focus on pain in rheumatoid arthritis. Semin Arthritis Rheum. 2021;51(1):278-284. doi: 10.1016/j.semarthrit.2020.10.008Crispino N, Ciccia F. JAK/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol. 2021;39(3):668-675.Crispino N, Ciccia F. JAK/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol. 2021;39(3):668-675.Каратеев АЕ, Погожева ЕЮ, Амирджанова ВН, Филатова ЕС, Лила АМ, Мазуров ВИ, и др. Оценка эффективности тофацитиниба при ревматоидном артрите в реальной клинической практике: взаимосвязь между снижением боли в первые 4 недели и активностью заболевания через 3–6 месяцев. Научно-практическая ревматология. 2021;59(4):394-400. doi: 10.47360/1995-4484-2021-394-400Karateev AE, Pogozheva EYu, Amirjanova VN, Filatova ES, Lila AM, Mazurov VI, et al. Evaluation of the effectiveness of Tofacitinib in rheumatoid arthritis in real clinical practice: The relationship between pain relief in the first 4 weeks and disease activity after 3–6 months. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2021;59(4):394-400. (In Russ.). doi: 10.47360/1995-4484-2021-394-400Cook AD, Pobjoy J, Steidl S, Dürr M, Braine EL, Turner AL, et al. Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development. Arthritis Res Ther. 2012;14:R199. doi: 10.1186/ar4037Cook AD, Pobjoy J, Steidl S, Dürr M, Braine EL, Turner AL, et al. Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development. Arthritis Res Ther. 2012;14:R199. doi: 10.1186/ar4037Lee KM, Prasad V, Achuthan A, Fleetwood AJ, Hamilton JA, Cook AD. Targeting GM-CSF for collagenase-induced osteoarthritis pain and disease in mice. Osteoarthritis Cartilage. 2020;28(4):486-491. doi: 10.1016/j.joca.2020.01.012Lee KM, Prasad V, Achuthan A, Fleetwood AJ, Hamilton JA, Cook AD. Targeting GM-CSF for collagenase-induced osteoarthritis pain and disease in mice. Osteoarthritis Cartilage. 2020;28(4):486-491. doi: 10.1016/j.joca.2020.01.012Choy EHS, Calabrese LH. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rheumatology (Oxford). 2018;57(11):1885-1895. doi: 10.1093/rheumatology/kex391Choy EHS, Calabrese LH. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rheumatology (Oxford). 2018;57(11):1885-1895. doi: 10.1093/rheumatology/kex391Лисицына ТА, Вельтищев ДЮ, Лила АМ, Насонов ЕЛ. Интерлейкин 6 как патогенетический фактор, опосредующий формирование клинических проявлений, и мишень для терапии ревматических заболеваний и депрессивных расстройств. Научно-практическая ревматология. 2019;57(3):318-327. doi: 10.14412/1995-44842019-318-327.Lisitsyna TA, Veltishchev DYu, Lila AM, Nasonov EL. Interleukin 6 as a pathogenic factor mediating clinical manifestations and a therapeutic target for rheumatic diseases and depressive disorders. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(3):318-327 doi: 10.14412/1995-44842019-318-327.Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: A systematic review and meta-analysis. Gastroenterology. 2020;158(6):1554-1573.e12. doi: 10.1053/j.gastro.2020.01.001Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: A systematic review and meta-analysis. Gastroenterology. 2020;158(6):1554-1573.e12. doi: 10.1053/j.gastro.2020.01.001Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234-243. doi: 10.1038/nrrheum.2017.23Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234-243. doi: 10.1038/nrrheum.2017.23Harigai M, Honda S. Selectivity of Janus kinase inhibitors in rheumatoid arthritis and other immune-mediated inflammatory diseases: Is expectation the root of all headache? Drugs. 2020;80(12):1183-1201. doi: 10.1007/s40265-020-01349-1Harigai M, Honda S. Selectivity of Janus kinase inhibitors in rheumatoid arthritis and other immune-mediated inflammatory diseases: Is expectation the root of all headache? Drugs. 2020;80(12):1183-1201. doi: 10.1007/s40265-020-01349-1Yates M, Mootoo A, Adas M, Bechman K, Rampes S, Patel V, et al. Venous thromboembolism risk with JAK inhibitors: A metaanalysis. Arthritis Rheumatol. 2021;73(5):779-788. doi: 10.1002/art.41580Yates M, Mootoo A, Adas M, Bechman K, Rampes S, Patel V, et al. Venous thromboembolism risk with JAK inhibitors: A metaanalysis. Arthritis Rheumatol. 2021;73(5):779-788. doi: 10.1002/art.41580Atzeni F, Popa CD, Nucera V, Nurmohamed MT. Safety of JAK inhibitors: Focus on cardiovascular and thromboembolic events. Expert Rev Clin Immunol. 2022 Feb 17:1-12. doi: 10.1080/1744666X.2022.2039630Atzeni F, Popa CD, Nucera V, Nurmohamed MT. Safety of JAK inhibitors: Focus on cardiovascular and thromboembolic events. Expert Rev Clin Immunol. 2022 Feb 17:1-12. doi: 10.1080/1744666X.2022.2039630Kretschmer S, Lee-Kirsch MA. Type I interferon-mediated autoinflammation and autoimmunity. Curr Opin Immunol. 2017;49:96102. doi: 10.1016/j.coi.2017.09.003Kretschmer S, Lee-Kirsch MA. Type I interferon-mediated autoinflammation and autoimmunity. Curr Opin Immunol. 2017;49:96102. doi: 10.1016/j.coi.2017.09.003Насонов ЕЛ, Авдеева АС. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;57(4):452-461. doi: 10.14412/1995-4484-2019452-461Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type I interferon: New evidence. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(4):452-461 (In Russ.). doi: 10.14412/1995-4484-2019452-461Gómez-Arias PJ, Gómez-García F, Hernández-Parada J, Montilla-López AM, Ruano J, Parra-Peralbo E. Efficacy and safety of Janus kinase inhibitors in type I interferon-mediated monogenic autoinflammatory disorders: A scoping review. Dermatol Ther (Heidelb). 2021;11(3):733-750. doi: 10.1007/s13555-021-00517-9Gómez-Arias PJ, Gómez-García F, Hernández-Parada J, Montilla-López AM, Ruano J, Parra-Peralbo E. Efficacy and safety of Janus kinase inhibitors in type I interferon-mediated monogenic autoinflammatory disorders: A scoping review. Dermatol Ther (Heidelb). 2021;11(3):733-750. doi: 10.1007/s13555-021-00517-9Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Sève P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2019;18(11):102390. doi: 10.1016/j.autrev.2019.102390Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Sève P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2019;18(11):102390. doi: 10.1016/j.autrev.2019.102390Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: Pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-1675. doi: 10.1093/rheumatology/kew431Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: Pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-1675. doi: 10.1093/rheumatology/kew431Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, et al. Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222-231. doi: 10.1016/S01406736(18)31363-1Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, et al. Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222-231. doi: 10.1016/S01406736(18)31363-1Hasni SA, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci PM, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12(1):3391. doi: 10.1038/s41467-021-23361-zHasni SA, Gupta S, Davis M, Poncio E, Temesgen-Oyelakin Y, Carlucci PM, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12(1):3391. doi: 10.1038/s41467-021-23361-zYou H, Zhang G, Wang Q, Zhang S, Zhao J, Tian X, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: The experience from a single centre. Ann Rheum Dis. 2019;78(10):1441-1443. doi: 10.1136/annrheumdis-2019-215455You H, Zhang G, Wang Q, Zhang S, Zhao J, Tian X, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: The experience from a single centre. Ann Rheum Dis. 2019;78(10):1441-1443. doi: 10.1136/annrheumdis-2019-215455Chen YL, Liu LX, Huang Q, Li XY, Hong XP, Liu DZ. Case report: Reversal of long-standing refractory diffuse non-scarring alopecia due to systemic lupus erythematosus following treatment with tofacitinib. Front Immunol. 2021;12:654376. doi: 10.3389/fimmu.2021.654376Chen YL, Liu LX, Huang Q, Li XY, Hong XP, Liu DZ. Case report: Reversal of long-standing refractory diffuse non-scarring alopecia due to systemic lupus erythematosus following treatment with tofacitinib. Front Immunol. 2021;12:654376. doi: 10.3389/fimmu.2021.654376Bonnardeaux E, Dutz JP. Oral tofacitinib citrate for recalcitrant cutaneous lupus. JAAD Case Rep. 2021;20:61-64. doi: 10.1016/j.jdcr.2021.09.030Bonnardeaux E, Dutz JP. Oral tofacitinib citrate for recalcitrant cutaneous lupus. JAAD Case Rep. 2021;20:61-64. doi: 10.1016/j.jdcr.2021.09.030Landon-Cardinal O, Guillaume-Jugnot P, Bolko L, Toquet S, Rigolet A, Hervier B, et al. JAK inhibitors: A promising molecular-targeted therapy in dermatomyositis [Abstract]. Arthritis Rheumatol. 2019;71(Suppl 10). URL: https://acrabstracts.org/abstract/jak-inhibitors-a-promising-molecular-targeted-therapyin-dermatomyositis (Accessed: 9th March 2022).Landon-Cardinal O, Guillaume-Jugnot P, Bolko L, Toquet S, Rigolet A, Hervier B, et al. JAK inhibitors: A promising molecular-targeted therapy in dermatomyositis [Abstract]. Arthritis Rheumatol. 2019;71(Suppl 10). URL: https://acrabstracts.org/ abstract/jak-inhibitors-a-promising-molecular-targeted-therapyin-dermatomyositis (Accessed: 9th March 2022).Paik JJ, Casciola-Rosen L, Shin JY, Albayda J, Tiniakou E, Leung DG, et al. Study of tofacitinib in refractory dermatomyositis: An open-label pilot study of ten patients. Arthritis Rheumatol. 2021;73(5):858-865. doi: 10.1002/art.41602Paik JJ, Casciola-Rosen L, Shin JY, Albayda J, Tiniakou E, Leung DG, et al. Study of tofacitinib in refractory dermatomyositis: An open-label pilot study of ten patients. Arthritis Rheumatol. 2021;73(5):858-865. doi: 10.1002/art.41602Papadopoulou C, Hong Y, Omoyinmi E, Brogan PA, Eleftheriou D. Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain. 2019; 142(3):e8. doi: 10.1093/brain/awz005Papadopoulou C, Hong Y, Omoyinmi E, Brogan PA, Eleftheriou D. Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain. 2019; 142(3):e8. doi: 10.1093/brain/awz005Le Voyer T, Gitiaux C, Authier FJ, Bodemer C, Melki I, Quartier P, et al. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: A monocentric retrospective study. Rheumatology (Oxford). 2021;60(12):5801-5808. doi: 10.1093/rheumatology/keab116Le Voyer T, Gitiaux C, Authier FJ, Bodemer C, Melki I, Quartier P, et al. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: A monocentric retrospective study. Rheumatology (Oxford). 2021;60(12):5801-5808. doi: 10.1093/rheumatology/keab116Kim H, Dill S, O’Brien M, Vian L, Li X, Manukyan M, et al. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheum Dis. 2020 Aug 25:annrheumdis-2020-218690. doi: 10.1136/annrheumdis-2020-218690.Kim H, Dill S, O’Brien M, Vian L, Li X, Manukyan M, et al. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheum Dis. 2020 Aug 25:annrheumdis-2020-218690. doi: 10.1136/annrheumdis-2020-218690.Sabbagh S, Almeida de Jesus A, Hwang S, Kuehn HS, Kim H, Jung L, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain. 2019;142(11):e59. doi: 10.1093/brain/awz293Sabbagh S, Almeida de Jesus A, Hwang S, Kuehn HS, Kim H, Jung L, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain. 2019;142(11):e59. doi: 10.1093/brain/awz293Yu Z, Wang L, Quan M, Zhang T, Song H. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: A pilot study and literature review. Rheumatology (Oxford). 2021;60(4):1700-1707. doi: 10.1093/rheumatology/keaa558Yu Z, Wang L, Quan M, Zhang T, Song H. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: A pilot study and literature review. Rheumatology (Oxford). 2021;60(4):1700-1707. doi: 10.1093/rheumatology/keaa558Ding Y, Huang B, Wang Y, Hou J, Chi Y, Zhou Z, Li J. Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis. Ann Rheum Dis. 2020;80(4):543-545. doi: 10.1136/annrheumdis-2020-218582Ding Y, Huang B, Wang Y, Hou J, Chi Y, Zhou Z, Li J. Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis. Ann Rheum Dis. 2020;80(4):543-545. doi: 10.1136/annrheumdis-2020-218582Kuwabara S, Tanimura S, Matsumoto S, Nakamura H, Horita T. Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis. Ann Rheum Dis. 2020;79(8):1125-1126. doi: 10.1136/annrheumdis-2019-216606Kuwabara S, Tanimura S, Matsumoto S, Nakamura H, Horita T. Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis. Ann Rheum Dis. 2020;79(8):1125-1126. doi: 10.1136/annrheumdis-2019-216606Zhu KJ, Yang PD, Xu Q. Tofacitinib treatment of refractory cutaneous leukocytoclastic vasculitis: A case report. Front Immunol. 2021;12:695768. doi: 10.3389/fimmu.2021.695768Zhu KJ, Yang PD, Xu Q. Tofacitinib treatment of refractory cutaneous leukocytoclastic vasculitis: A case report. Front Immunol. 2021;12:695768. doi: 10.3389/fimmu.2021.695768You H, Xu D, Hou Y, Zhou J, Wang Q, Li M, et al. Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford). 2021;60(5):2472-2477. doi: 10.1093/rheumatology/keaa613You H, Xu D, Hou Y, Zhou J, Wang Q, Li M, et al. Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford). 2021;60(5):2472-2477. doi: 10.1093/rheumatology/keaa613Karalilova RV, Batalov ZA, Sapundzhieva TL, MatucciCerinic M, Batalov AZ. Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound. Rheumatol Int. 2021;41(10):17431753. doi: 10.1007/s00296-021-04956-7Karalilova RV, Batalov ZA, Sapundzhieva TL, MatucciCerinic M, Batalov AZ. Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound. Rheumatol Int. 2021;41(10):17431753. doi: 10.1007/s00296-021-04956-7Komai T, Shoda H, Hanata N, Fujio K. Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis. Scand J Rheumatol. 2018;47(6):505-506. doi: 10.1080/03009742.2017.1387673Komai T, Shoda H, Hanata N, Fujio K. Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis. Scand J Rheumatol. 2018;47(6):505-506. doi: 10.1080/03009742.2017.1387673Meshkov AD, Novikov PI, Zhilyaev EV, Ilevsky IDJ, Moiseev SV. Tofacitinib in steroid-dependent relapsing polychondritis. Ann Rheum Dis. 2019;78(7):e72. doi: 10.1136/annrheumdis-2018-213554Meshkov AD, Novikov PI, Zhilyaev EV, Ilevsky IDJ, Moiseev SV. Tofacitinib in steroid-dependent relapsing polychondritis. Ann Rheum Dis. 2019;78(7):e72. doi: 10.1136/annrheumdis-2018-213554Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med. 2018;379(26):2540-2546. doi: 10.1056/NEJMoa1805958Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med. 2018;379(26):2540-2546. doi: 10.1056/NEJMoa1805958Rimar D, Alpert A, Starosvetsky E, Rosner I, Slobodin G, Rozenbaum M, et al. Tofacitinib for polyarteritis nodosa: A tailored therapy. Ann Rheum Dis. 2016;75(12):2214-2216. doi: 10.1136/annrheumdis-2016-209330Rimar D, Alpert A, Starosvetsky E, Rosner I, Slobodin G, Rozenbaum M, et al. Tofacitinib for polyarteritis nodosa: A tailored therapy. Ann Rheum Dis. 2016;75(12):2214-2216. doi: 10.1136/annrheumdis-2016-209330Chapman S, Kwa M, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: Part I. A comprehensive review. J Am Acad Dermatol. 2022;86(2):406-413. doi: 10.1016/j.jaad.2021.07.002Chapman S, Kwa M, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: Part I. A comprehensive review. J Am Acad Dermatol. 2022;86(2):406-413. doi: 10.1016/j.jaad.2021.07.002Chapman S, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: Part II. A comprehensive review. J Am Acad Dermatol. 2022;86(2):414-422. doi: 10.1016/j.jaad.2021.06.873Chapman S, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: Part II. A comprehensive review. J Am Acad Dermatol. 2022;86(2):414-422. doi: 10.1016/j.jaad.2021.06.873Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология. 2020;58(2):123-132. doi: 10.14412/1995-4484-2020-123-132Nasonov EL. Coronavirus Disease 2019 (COVID-19): A rheumatologist’s thoughts. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2020;58(2):123132 (In Russ.). doi: 10.14412/1995-4484-2020-123-132Schett G, Manger B, Simon D, Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol. 2020;16(8):465-470. doi: 10.1038/s41584-020-0451-zSchett G, Manger B, Simon D, Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol. 2020;16(8):465-470. doi: 10.1038/s41584-020-0451-zНасонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19) и аутоиммунитет. Научно-практическая ревматология. 2021;59(1):5-30. doi: 10.47360/1995-4484-2021-5-30Nasonov EL. Coronavirus disease 2019 (COVID-19) and autoimmunity. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2021;59(1):530 (In Russ.). doi: 10.47360/1995-4484-2021-5-30Насонов ЕЛ. Коронавирусная болезни 2019 (COVID-19): вклад ревматологии. Терапевтический архив. 2021;93(5):537550. doi: 10.26442/00403660.2021.05.200799Nasonov EL. Coronavirus disease (COVID-19): Contribution of rheumatology. Terapevticheskii arkhiv. 2021;93(5):537-550 (In Russ.). doi: 10.26442/00403660.2021.05.200799Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARSCoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141-154. doi: 10.1038/s41579-020-00459-7Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARSCoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141-154. doi: 10.1038/s41579-020-00459-7Wang Y, Perlman S. COVID-19: Inflammatory profile. Annu Rev Med. 2022;73:65-80. doi: 10.1146/annurev-med-042220-012417Wang Y, Perlman S. COVID-19: Inflammatory profile. Annu Rev Med. 2022;73:65-80. doi: 10.1146/annurev-med-042220-012417Fajgenbaum DC, June CH, Cytokine storm. N Engl J Med. 2020;383:2255-2273. doi: 10.1056/NEJMra2026131Fajgenbaum DC, June CH, Cytokine storm. N Engl J Med. 2020;383:2255-2273. doi: 10.1056/NEJMra2026131Weatherhead JE, Clark E, Vogel TP, Atmar RL, Kulkarni PA. Inflammatory syndromes associated with SARS-CoV-2 infection: Dysregulation of the immune response across the age spectrum. J Clin Invest. 2020;130(12):6194-6197. doi: 10.1172/JCI145301Weatherhead JE, Clark E, Vogel TP, Atmar RL, Kulkarni PA. Inflammatory syndromes associated with SARS-CoV-2 infection: Dysregulation of the immune response across the age spectrum. J Clin Invest. 2020;130(12):6194-6197. doi: 10.1172/JCI145301Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12(5):259-268. doi: 10.1038/nrrheum.2015.179Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12(5):259-268. doi: 10.1038/nrrheum.2015.179Akbari H, Tabrizi R, Lankarani KB, Aria H, Vakili S, Asadian F, et al. The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Life Sci. 2020;258:118167. doi: 10.1016/j.lfs.2020.118167Akbari H, Tabrizi R, Lankarani KB, Aria H, Vakili S, Asadian F, et al. The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Life Sci. 2020;258:118167. doi: 10.1016/j.lfs.2020.118167Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8(12):1233-1244. doi: 10.1016/S2213-2600(20)30404-5Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8(12):1233-1244. doi: 10.1016/S2213-2600(20)30404-5Nissen CB, Sciascia S, de Andrade D, Atsumi T, Bruce IN, Cron RQ, et al. The role of antirheumatics in patients with COVID-19. Lancet Rheumatol. 2021;3(6):e447-e459. doi: 10.1016/S2665-9913(21)00062-XNissen CB, Sciascia S, de Andrade D, Atsumi T, Bruce IN, Cron RQ, et al. The role of antirheumatics in patients with COVID-19. Lancet Rheumatol. 2021;3(6):e447-e459. doi: 10.1016/S2665-9913(21)00062-XNasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020;131:110698. doi: 10.1016/j.biopha.2020.110698Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020;131:110698. doi: 10.1016/j.biopha.2020.110698Fagni F, Simon D, Tascilar K, Schoenau V, Sticherling M, Neurath MF, et al. COVID-19 and immune-mediated inflammatory diseases: Effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol. 2021;3(10):e724-e736. doi: 10.1016/S2665-9913(21)00247-2Fagni F, Simon D, Tascilar K, Schoenau V, Sticherling M, Neurath MF, et al. COVID-19 and immune-mediated inflammatory diseases: Effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol. 2021;3(10):e724-e736. doi: 10.1016/S2665-9913(21)00247-2Stebbing J, Krishnan V, de Bono S, Ottaviani S, Casalini G, Richardson PJ, et al.; Sacco Baricitinib Study Group. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med. 2020;12(8):e12697. doi: 10.15252/emmm.202012697Stebbing J, Krishnan V, de Bono S, Ottaviani S, Casalini G, Richardson PJ, et al.; Sacco Baricitinib Study Group. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med. 2020;12(8):e12697. doi: 10.15252/emmm.202012697Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al.; ACTT-2 Study Group Members. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2021;384(9):795-807. doi: 10.1056/NEJMoa2031994Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al.; ACTT-2 Study Group Members. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2021;384(9):795-807. doi: 10.1056/NEJMoa2031994Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al.; COV-BARRIER Study Group. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407-1418. doi: 10.1016/S22132600(21)00331-3Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al.; COV-BARRIER Study Group. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407-1418. doi: 10.1016/S22132600(21)00331-3Ely EW, Ramanan AV, Kartman CE, de Bono S, Kuai R, Piruzeli MLB, et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: Results of a randomized, placebo-controlled trial. Medrxiv. 2021.10.11.21263897. doi: 10.1101/2021.10.11.21263897Ely EW, Ramanan AV, Kartman CE, de Bono S, Kuai R, Piruzeli MLB, et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: Results of a randomized, placebo-controlled trial. Medrxiv. 2021.10.11.21263897. doi: 10.1101/2021.10.11.21263897Titanji BK, Farley MM, Mehta A, Connor-Schuler R, Moanna A, Cribbs SK, et al. Use of baricitinib in patients with moderate to severe coronavirus disease 2019. Clin Infect Dis. 2021;72(7):1247-1250. doi: 10.1093/cid/ciaa879Titanji BK, Farley MM, Mehta A, Connor-Schuler R, Moanna A, Cribbs SK, et al. Use of baricitinib in patients with moderate to severe coronavirus disease 2019. Clin Infect Dis. 2021;72(7):1247-1250. doi: 10.1093/cid/ciaa879Rodriguez-Garcia JL, Sanchez-Nievas G, Arevalo-Serrano J, Garcia-Gomez C, Jimenez-Vizuete JM, Martinez-Alfaro E. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. Rheumatology (Oxford). 2021;60(1):399-407. doi: 10.1093/rheumatology/keaa587Rodriguez-Garcia JL, Sanchez-Nievas G, Arevalo-Serrano J, Garcia-Gomez C, Jimenez-Vizuete JM, Martinez-Alfaro E. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. Rheumatology (Oxford). 2021;60(1):399-407. doi: 10.1093/rheumatology/keaa587Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020;81(2):318-356. doi: 10.1016/j.jinf.2020.04.017Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020;81(2):318-356. doi: 10.1016/j.jinf.2020.04.017Cantini F, Niccoli L, Nannini C, Matarrese D, Natale MED, Lotti P, et al. Beneficial impact of baricitinib in COVID-19 mod erate pneumonia; multicentre study. J Infect. 2020;81(4):647-679. doi: 10.1016/j.jinf.2020.06.052Cantini F, Niccoli L, Nannini C, Matarrese D, Natale MED, Lotti P, et al. Beneficial impact of baricitinib in COVID-19 mod erate pneumonia; multicentre study. J Infect. 2020;81(4):647-679. doi: 10.1016/j.jinf.2020.06.052Abizanda P, Calbo Mayo JM, Mas Romero M, Cortés Zamora EB, Tabernero Sahuquillo MT, et al. Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia. J Am Geriatr Soc. 2021;69(10):2752-2758. doi: 10.1111/jgs.17357Abizanda P, Calbo Mayo JM, Mas Romero M, Cortés Zamora EB, Tabernero Sahuquillo MT, et al. Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia. J Am Geriatr Soc. 2021;69(10):2752-2758. doi: 10.1111/jgs.17357Bronte V, Ugel S, Tinazzi E, Vella A, De Sanctis F, Canè S, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020;130(12):6409-6416. doi: 10.1172/JCI141772Bronte V, Ugel S, Tinazzi E, Vella A, De Sanctis F, Canè S, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020;130(12):6409-6416. doi: 10.1172/JCI141772Rosas J, Liaño FP, Cantó ML, Barea JMC, Beser AR, Rabasa JTA, et al.; COVID19-HMB Group. Experience with the use of baricitinib and tocilizumab monotherapy or combined, in patients with interstitial pneumonia secondary to coronavirus COVID19: A real-world study. Reumatol Clin (Engl Ed). 2020;18(3):150-156. doi: 10.1016/j.reuma.2020.10.009Rosas J, Liaño FP, Cantó ML, Barea JMC, Beser AR, Rabasa JTA, et al.; COVID19-HMB Group. Experience with the use of baricitinib and tocilizumab monotherapy or combined, in patients with interstitial pneumonia secondary to coronavirus COVID19: A real-world study. Reumatol Clin (Engl Ed). 2020;18(3):150-156. doi: 10.1016/j.reuma.2020.10.009Stebbing J, Sánchez Nievas G, Falcone M, Youhanna S, Richardson P, Ottaviani S, et al. JAK inhibition reduces SARSCoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci Adv. 2021;7(1):eabe4724. doi: 10.1126/sciadv.abe4724Stebbing J, Sánchez Nievas G, Falcone M, Youhanna S, Richardson P, Ottaviani S, et al. JAK inhibition reduces SARSCoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci Adv. 2021;7(1):eabe4724. doi: 10.1126/sciadv.abe4724Pérez-Alba E, Nuzzolo-Shihadeh L, Aguirre-García GM, Espinosa-Mora J, Lecona-Garcia JD, Flores-Pérez RO, et al. Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis. J Microbiol Immunol Infect. 2021;54(5):787-793. doi: 10.1016/j.jmii.2021.05.009Pérez-Alba E, Nuzzolo-Shihadeh L, Aguirre-García GM, Espinosa-Mora J, Lecona-Garcia JD, Flores-Pérez RO, et al. Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis. J Microbiol Immunol Infect. 2021;54(5):787-793. doi: 10.1016/j.jmii.2021.05.009Masiá M, Padilla S, García JA, García-Abellán J, Navarro A, Guillén L, et al. Impact of the addition of baricitinib to standard of care including tocilizumab and corticosteroids on mortality and safety in severe COVID-19. Front Med (Lausanne). 2021;8:749657. doi: 10.3389/fmed.2021.749657Masiá M, Padilla S, García JA, García-Abellán J, Navarro A, Guillén L, et al. Impact of the addition of baricitinib to standard of care including tocilizumab and corticosteroids on mortality and safety in severe COVID-19. Front Med (Lausanne). 2021;8:749657. doi: 10.3389/fmed.2021.749657Melikhov O, Kruglova T, Lytkina K, Melkonyan G, Prokhorovich E, Putsman G, et al. Use of Janus kinase inhibitors in COVID-19: A prospective observational series in 522 individuals. Ann Rheum Dis. 2021;80(9):1245-1246. doi: 10.1136/annrheumdis-2021-220049Melikhov O, Kruglova T, Lytkina K, Melkonyan G, Prokhorovich E, Putsman G, et al. Use of Janus kinase inhibitors in COVID-19: A prospective observational series in 522 individuals. Ann Rheum Dis. 2021;80(9):1245-1246. doi: 10.1136/annrheumdis-2021-220049Guimarães PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, et al.; STOP-COVID Trial Investigators. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N Engl J Med. 2021;385(5):406-415. doi: 10.1056/NEJMoa2101643Guimarães PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, et al.; STOP-COVID Trial Investigators. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N Engl J Med. 2021;385(5):406-415. doi: 10.1056/NEJMoa2101643Maslennikov R, Ivashkin V, Vasilieva E, Chipurik M, Semikova P, Semenets V, et al. Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19. Pulm Pharmacol Ther. 2021;69:102039. doi: 10.1016/j.pupt.2021.102039Maslennikov R, Ivashkin V, Vasilieva E, Chipurik M, Semikova P, Semenets V, et al. Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19. Pulm Pharmacol Ther. 2021;69:102039. doi: 10.1016/j.pupt.2021.102039Hayek ME, Mansour M, Ndetan H, Burkes Q, Corkern R, Dulli A, et al. Anti-inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent in a predominantly African American cohort. Mayo Clin Proc Innov Qual Outcomes. 2021;5(3):605-613. doi: 10.1016/j.mayocpiqo.2021.03.007Hayek ME, Mansour M, Ndetan H, Burkes Q, Corkern R, Dulli A, et al. Anti-inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent in a predominantly African American cohort. Mayo Clin Proc Innov Qual Outcomes. 2021;5(3):605-613. doi: 10.1016/j.mayocpiqo.2021.03.007Singh PK, Lalwani LK, Govindagoudar MB, Aggarwal R, Chaudhry D, Kumar P, et al. Tofacitinib associated with reduced intubation rates in the management of severe COVID-19 pneumonia: A preliminary experience. Indian J Crit Care Med. 2021;25(10):1108-1112. doi: 10.5005/jp-journals-10071-23964Singh PK, Lalwani LK, Govindagoudar MB, Aggarwal R, Chaudhry D, Kumar P, et al. Tofacitinib associated with reduced intubation rates in the management of severe COVID-19 pneumonia: A preliminary experience. Indian J Crit Care Med. 2021;25(10):1108-1112. doi: 10.5005/jp-journals-10071-23964Насонов ЕЛ, Лила АМ, Мазуров ВИ, Белов БС, Каратеев АЕ, Дубинина ТВ, и др. Коронавирусная болезнь 2019 (COVID19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2021;59(3):239-254. doi: 10.47360/1995-4484-2021239-254Nasonov EL, Lila AM, Mazurov VI, Belov BS, Karateev AE, Dubinina TV, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated rheumatic diseases. Recommendations of the Association of Rheumatologists of Russia. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2021;59(3):239-254 (In Russ.). doi: 10.47360/1995-4484-2021239-254Насонов ЕЛ, Белов БС, Лила АМ, Аронова ЕС, Гриднева ГИ, Кудрявцева АВ, и др. Течение и исходы COVID-19 у пациентов с иммуновоспалительными ревматическими заболеваниями: предварительные данные регистра НИИР/АРР-COVID-19 и обзор литературы. Научнопрактическая ревматология. 2021;59(6):666-675. oi: 10.47360/19954484-2021-666-675Nasonov EL, Belov BS, Lila AM, Aronova ES, Gridneva GI, Kudryavtseva AV, et al. Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2021;59(6):666-675 (In Russ.). doi: 10.47360/19954484-2021-666-675Izadi Z, Brenner EJ, Mahil SK, Dand N, Yiu ZZN, Yates M, et al.; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Allianc; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Alliance (GRA). Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open. 2021;4(10):e2129639. doi: 10.1001/jamanetworkopen.2021.29639Izadi Z, Brenner EJ, Mahil SK, Dand N, Yiu ZZN, Yates M, et al.; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Allianc; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Alliance (GRA). Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open. 2021;4(10):e2129639. doi: 10.1001/jamanetworkopen.2021.29639Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al.; COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930-942. doi: 10.1136/annrheumdis-2020-219498Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al.; COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930-942. doi: 10.1136/annrheumdis-2020-219498Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, et al.; COVID-19 Global Rheumatology Alliance. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021;80(9):1137-1146. doi: 10.1136/annrheumdis-2021-220418Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, et al.; COVID-19 Global Rheumatology Alliance. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021;80(9):1137-1146. doi: 10.1136/annrheumdis-2021-220418Dernoncourt A, Schmidt J, Duhaut P, Liabeuf S, GrasChampel V, Masmoudi K, et al. COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database. Fundam Clin Pharmacol. 2022;36(1):199-209. doi: 10.1111/fcp.12695Dernoncourt A, Schmidt J, Duhaut P, Liabeuf S, GrasChampel V, Masmoudi K, et al. COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database. Fundam Clin Pharmacol. 2022;36(1):199-209. doi: 10.1111/fcp.12695Seror R, Camus M, Salmon JH, Roux C, Dernis E, Basch A, et al. Do JAK inhibitors affect immune response to COVID19 vaccination? Data from the MAJIK-SFR Registry. Lancet Rheumatol. 2022;4(1):e8-e11. doi: 10.1016/S2665-9913(21)00314-3Seror R, Camus M, Salmon JH, Roux C, Dernis E, Basch A, et al. Do JAK inhibitors affect immune response to COVID19 vaccination? Data from the MAJIK-SFR Registry. Lancet Rheumatol. 2022;4(1):e8-e11. doi: 10.1016/S2665-9913(21)00314-3Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016;75(4):687-695. doi: 10.1136/annrheumdis-2014-207191Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016;75(4):687-695. doi: 10.1136/annrheumdis-2014-207191Winthrop KL, Bingham CO 3rd, Komocsar WJ, Bradley J, Issa M, Klar R, et al. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: Results from a long-term extension trial substudy. Arthritis Res Ther. 2019;21(1):102. doi: 10.1186/s13075-019-1883-1Winthrop KL, Bingham CO 3rd, Komocsar WJ, Bradley J, Issa M, Klar R, et al. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: Results from a long-term extension trial substudy. Arthritis Res Ther. 2019;21(1):102. doi: 10.1186/s13075-019-1883-1Белов БС, Лила АМ, Насонов ЕЛ. Вакцинация против SARS-CoV-2 при ревматических заболеваниях: вопросы безопасности. Научно-практическая ревматология. 2022;60(1):21-31. doi: 10.47360/19954484-2022-21-31Belov BS, Lila AM, Nasonov EL. Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2022;60(1):21-31. (In Russ.). doi: 10.47360/19954484-2022-21-31Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: A consensus statement. Ann Rheum Dis. 2021;80(1):71-87. doi: 10.1136/annrheumdis-2020-218398Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: A consensus statement. Ann Rheum Dis. 2021;80(1):71-87. doi: 10.1136/annrheumdis-2020-218398Goodman SM, Springer B, Guyatt G, Abdel MP, Dasa V, George M, et al. 2017 American College of Rheumatology/ American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Rheumatol. 2017;69(8):15381551. doi: 10.1002/art.40149Goodman SM, Springer B, Guyatt G, Abdel MP, Dasa V, George M, et al. 2017 American College of Rheumatology/ American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Rheumatol. 2017;69(8):15381551. doi: 10.1002/art.40149Landewé RBM, Kroon FPB, Alunno A, Najm A, Bijlsma JW, Burmester GR, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: The November 2021 update. Ann Rheum Dis. 2022 Feb 23:annrheumdis-2021-222006. doi: 10.1136/annrheumdis-2021-222006Landewé RBM, Kroon FPB, Alunno A, Najm A, Bijlsma JW, Burmester GR, et al. EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: The November 2021 update. Ann Rheum Dis. 2022 Feb 23:annrheumdis-2021-222006. doi: 10.1136/annrheumdis-2021-222006M ikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: Version 3. Arthritis Rheumatol. 2021;73(2):e1-e12. doi: 10.1002/art.41596M ikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: Version 3. Arthritis Rheumatol. 2021;73(2):e1-e12. doi: 10.1002/art.41596Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 1. Arthritis Rheumatol. 2021;73(7):1093-1107. doi: 10.1002/art.41734Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 1. Arthritis Rheumatol. 2021;73(7):1093-1107. doi: 10.1002/art.41734McInnes IB, Szekanecz Z, McGonagle D, Maksymowych WP, Pfeil A, Lippe R, et al. A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. Rheumatology (Oxford). 2021 Oct 20:keab740. doi: 10.1093/rheumatology/keab740McInnes IB, Szekanecz Z, McGonagle D, Maksymowych WP, Pfeil A, Lippe R, et al. A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. Rheumatology (Oxford). 2021 Oct 20:keab740. doi: 10.1093/rheumatology/keab740Ridgley LA, Anderson AE, Pratt AG. What are the dominant cytokines in early rheumatoid arthritis? Curr Opin Rheumatol. 2018;30(2):207-214. doi: 10.1097/BORRidgley LA, Anderson AE, Pratt AG. What are the dominant cytokines in early rheumatoid arthritis? Curr Opin Rheumatol. 2018;30(2):207-214. doi: 10.1097/BORMylonas A, Conrad C. Psoriasis: Classical vs. paradoxical. The yin-yang of TNF and type I interferon. Front Immunol. 2018;9:2746. doi: 10.3389/fimmu.2018.02746Mylonas A, Conrad C. Psoriasis: Classical vs. paradoxical. The yin-yang of TNF and type I interferon. Front Immunol. 2018;9:2746. doi: 10.3389/fimmu.2018.02746Conrad C, Di Domizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018;9(1):25. doi: 10.1038/s41467-017-02466-4Conrad C, Di Domizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018;9(1):25. doi: 10.1038/s41467-017-02466-4Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, et al. Immunogenicity of biologics in chronic inflammatory diseases: A systematic review. BioDrugs. 2017;31(4):299316. doi: 10.1007/s40259-017-0231-8Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, et al. Immunogenicity of biologics in chronic inflammatory diseases: A systematic review. BioDrugs. 2017;31(4):299316. doi: 10.1007/s40259-017-0231-8Насонов ЕЛ, Олюнин ЮА, Лила АМ. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии. Научно-практическая ревматология. 2018;56(3):263-271. doi: 10.14412/1995-4484-2018263-271Nasonov EL, Olyunin YuA, Lila AM. Rheumatoid arthritis: The problems of remission and therapy resistance. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):263-271 (In Russ.). doi: 10.14412/1995-4484-2018263-271Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(1):17-33. doi: 10.1038/s41584-020-00541-7Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(1):17-33. doi: 10.1038/s41584-020-00541-7Emery P, Pope JE, Kruger K, Lippe R, DeMasi R, Lula S, et al. Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: A systematic review. Adv Ther. 2018;35(10):1535-1563. doi: 10.1007/s12325-0180757-2Emery P, Pope JE, Kruger K, Lippe R, DeMasi R, Lula S, et al. Efficacy of monotherapy with biologics and JAK inhibitors for the treatment of rheumatoid arthritis: A systematic review. Adv Ther. 2018;35(10):1535-1563. doi: 10.1007/s12325-0180757-2Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al.; ORAL Surveillance Investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316-326. doi: 10.1056/NEJMoa2109927Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al.; ORAL Surveillance Investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316-326. doi: 10.1056/NEJMoa2109927Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022 Jan 13:annrheumdis-2021-221915. doi: 10.1136/annrheumdis-2021-221915Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022 Jan 13:annrheumdis-2021-221915. doi: 10.1136/annrheumdis-2021-221915Winthrop KL, Cohen DB. Oral surveillance and JAK inhibitor safety: The theory of relativity. Nat Rev Rheumatol. 2022 Mar 22:1-4. doi: 10.1038/s41584-022-00767-7Winthrop KL, Cohen DB. Oral surveillance and JAK inhibitor safety: The theory of relativity. Nat Rev Rheumatol. 2022 Mar 22:1-4. doi: 10.1038/s41584-022-00767-7Burke JR, Cheng L, Gillooly KM, Strnad J, Zupa-Fernandez A, Catlett IM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11(502):eaaw1736. doi: 10.1126/scitranslmed.aaw1736Burke JR, Cheng L, Gillooly KM, Strnad J, Zupa-Fernandez A, Catlett IM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11(502):eaaw1736. doi: 10.1126/scitranslmed.aaw1736Li H, Tsokos GC. IL-23/IL-17 axis in inflammatory rheumatic diseases. Clin Rev Allergy Immunol. 2021;60(1):31-45. doi: 10.1007/s12016-020-08823-4Li H, Tsokos GC. IL-23/IL-17 axis in inflammatory rheumatic diseases. Clin Rev Allergy Immunol. 2021;60(1):31-45. doi: 10.1007/s12016-020-08823-4Schinocca C, Rizzo C, Fasano S, Grasso G, La Barbera L, Ciccia F, et al. Role of the IL-23/IL-17 pathway in rheumatic diseases: An overview. Front Immunol. 2021;12:637829. doi: 10.3389/fimmu.2021.637829Schinocca C, Rizzo C, Fasano S, Grasso G, La Barbera L, Ciccia F, et al. Role of the IL-23/IL-17 pathway in rheumatic diseases: An overview. Front Immunol. 2021;12:637829. doi: 10.3389/fimmu.2021.637829P app K, Gordon K, Thaçi D, Morita A, Gooderham M, Foley P, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379(14):1313-1321. doi: 10.1056/NEJMoa1806382P app K, Gordon K, Thaçi D, Morita A, Gooderham M, Foley P, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379(14):1313-1321. doi: 10.1056/NEJMoa1806382Mease PJ, Deodhar AA, van der Heijde D, Behrens F, Kivitz AJ, Neal J, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022 Mar 3:annrheumdis-2021-221664. doi: 10.1136/annrheumdis-2021-221664Mease PJ, Deodhar AA, van der Heijde D, Behrens F, Kivitz AJ, Neal J, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022 Mar 3:annrheumdis-2021-221664. doi: 10.1136/annrheumdis-2021-221664Blunt MD, Koehrer S, Dobson RC, Larrayoz M, Wilmore S, Hayman A, et al. The dual Syk/JAK inhibitor cerdulatinib antagonizes B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(9):2313-2324. doi: 10.1158/1078-0432.CCR-16-1662Blunt MD, Koehrer S, Dobson RC, Larrayoz M, Wilmore S, Hayman A, et al. The dual Syk/JAK inhibitor cerdulatinib antagonizes B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(9):2313-2324. doi: 10.1158/1078-0432.CCR-16-1662Deng GM, Kyttaris VC, Tsokos GC. Targeting Syk in autoimmune rheumatic diseases. Front Immunol. 2016;7:78. doi: 10.3389/fimmu.2016.00Deng GM, Kyttaris VC, Tsokos GC. Targeting Syk in autoimmune rheumatic diseases. Front Immunol. 2016;7:78. doi: 10.3389/fimmu.2016.00Menet CJ. A dual inhibition, a better solution: Development of a JAK1/TYK2 inhibitor. J Med Chem. 2018;61(19):8594-8596. doi: 10.1021/acs.jmedchem.8b01397Menet CJ. A dual inhibition, a better solution: Development of a JAK1/TYK2 inhibitor. J Med Chem. 2018;61(19):8594-8596. doi: 10.1021/acs.jmedchem.8b01397

The authors declare that there are no conflicts of interest present.